Skip to Content
Merck
All Photos(1)

Key Documents

SRP2155

Sigma-Aldrich

HCV-NS4A/NS3-3 Protease,strain NZL1 from hepatitis C virus

recombinant, expressed in E. coli, ≥80% (SDS-PAGE)

Synonym(s):

Hepatitis C virus NS3 protease, NS3, NS4ANS3 complex, pfam02907

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352200
NACRES:
NA.26

biological source

hepatitis C virus

recombinant

expressed in E. coli

Assay

≥80% (SDS-PAGE)

form

frozen liquid

mol wt

~22.7 kDa

packaging

pkg of 10 μg

storage condition

avoid repeated freeze/thaw cycles

concentration

700 μg/mL

color

colorless to clear

NCBI accession no.

D17763

UniProt accession no.

Q81258

shipped in

dry ice

storage temp.

−70°C

Gene Information

hepatitis C virus ... HCVgp1(951475)

Biochem/physiol Actions

Persistent infection with hepatitis C virus (HCV) is a common cause of chronic liver disease, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HCV is an enveloped, single-stranded RNA virus with a 9.6-kb positive-polarity genome, which encodes a polyprotein precursor of about 3,000 amino acids. The HCV polyprotein is proteolytically processed by cellular and HCV proteases into at least 10 distinct products. NS3 serine protease and helicase as well as NS5B RNA-dependent RNA polymerase are believed to be components of a replication complex responsible for viral RNA replication and have been shown to be essential for the HCV replication in chimpanzees. These HCV enzymes have been the major targets for the development of HCV-specific therapeutics during the past decade. The HCV NS3/4A protease is responsible for cleavage at four sites within the HCV polyprotein to generate the N termini of the NS4A, NS4B, NS5A, and NS5B proteins. It has been shown that the central region (amino acids 21-30) of the 54-residue NS4A protein is essential and sufficient for the enhancement of proteolytic activity of the NS3 serine protease. In recent phase I trials, a 2-3-log reduction of HCV viral load was observed after a 2-day treatment with a serine protease inhibitor, which provided the first proof-of-concept evidence that HCV NS3/4A protease inhibitors could be a new therapeutic option for hepatitis C patients.

Physical form

Clear and colorless frozen liquid solution

Preparation Note

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. While working, please keep sample on ice.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The natural history of hepatitis C virus (HCV) infection.
Chen SL and Morgan TR
International Journal of Medical Sciences, 3, 47-52 (2006)
A A Kolykhalov et al.
Journal of virology, 74(4), 2046-2051 (2000-01-22)
Hepatitis C virus (HCV) infection is a widespread major human health concern. Significant obstacles in the study of this virus include the absence of a reliable tissue culture system and a small-animal model. Recently, we constructed full-length HCV cDNA clones
Blight, K. J., et al.
Antiviral Ther., 3, 71-81 (1998)
M J Alter
Hepatology (Baltimore, Md.), 26(3 Suppl 1), 62S-65S (1997-09-26)
In the United States, the annual number of newly acquired acute hepatitis C virus (HCV) infections has declined from an estimated 180,000 in the mid 1980s to an estimated 28,000 in 1995. Approximately 25% to 30% of these infections are

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service